Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms

被引:1
|
作者
Zhang, Yuhui [1 ]
Han, Yingdi [1 ]
Teng, Guangshuai [1 ]
Du, Chenxiao [1 ]
Gao, Shan [1 ]
Yuan, Weiping [2 ]
Zhang, Lei [2 ]
Bai, Jie [1 ]
机构
[1] Second Hosp Tianjin Med Univ, Dept Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 08期
基金
中国国家自然科学基金;
关键词
clinical characteristics; myeloproliferative neoplasms; risk factors; secondary cancer; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; ADULT PATIENTS; SOLID TUMORS; CANCER; TRANSFORMATION; SURVIVAL;
D O I
10.1002/cam4.5666
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe clinical characteristics and survival of patients with myeloproliferative neoplasms (MPNs) with secondary cancer were analyzed to explore the possible risk factors for secondary cancer in MPN patients. MethodsThe clinical characteristics of 1060 Chinese patients with MPN were retrospectively analyzed. The Kaplan-Meier method was used to analyze the survival. The Cox multivariate regression model was used to analyze the risk factors for developing secondary cancer in patients with MPNs. ResultsThe 1060 patients with MPN had a median follow-up of 10 years (range 1-50) and a median age of 55 years (range 21-86), and 497 (45.2%) were male. The proportion of PV, ET, and PMF was 52.2%, 33.5%, and 14.3%, respectively. About 28.1% (298/1060) of 1060 MPN patients died. The median survival times of the PV, ET, and PMF groups were 20, 24, and 12 years, respectively (p < 0.0001). In age- and sex-matched healthy Chinese patients, the standardized incidence ratio (SIR) value of developing secondary cancer in MPN patients was 6.41 (95% CI: 4.90-9.48). The median survival time was 14 years in the MPN with secondary cancer group. The Cox multivariate analysis showed that age >= 65 years (p < 0.0001, HR = 5.027, 95% CI [2.823, 8.952]), MF-1 (p = 0.001, HR = 2.887, 95% CI [1.503, 5.545]) were risk factors for developing secondary cancer. ConclusionsThe survival of MPN patients with secondary cancer was significantly worse than that of patients without secondary cancer. Compared with normal subjects, MPN patients had a 6.41-fold increased risk of developing secondary cancer, and age >= 65 years and MF-1 were risk factors for developing secondary cancer in MPN patients.
引用
收藏
页码:9236 / 9246
页数:11
相关论文
共 50 条
  • [1] Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
    Stempel, Jessica M.
    Wang, Rong
    Shallis, Rory Michael
    Huntington, Scott F.
    Zeidan, Amer M.
    Neparidze, Natalia
    Di, Mengyang
    Ma, Xiaomei
    Podoltsev, Nikolai A.
    BLOOD, 2022, 140 : 11004 - 11006
  • [2] Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
    Wang, Rong
    Shallis, Rory M.
    Stempel, Jessica M.
    Huntington, Scott F.
    Zeidan, Amer M.
    Gore, Steven D.
    Ma, Xiaomei
    Podoltsev, Nikolai A.
    BLOOD ADVANCES, 2023, 7 (05) : 734 - 743
  • [3] Incidence, Risk Factors, and Prognostic Implications of Heart Failure Hospitalizations Among Patients with Myeloproliferative Neoplasms
    Leiva, Orly
    Soo, Steven
    Smilowitz, Nathaniel
    Reynolds, Harmony
    Shah, Binita
    Bernard, Samuel
    Lee, Michelle Hyunju
    How, Chi-Joan
    Hobbs, Gabriela S.
    BLOOD, 2024, 144 : 3188 - 3189
  • [4] A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database
    Brunner, Andrew M.
    Hobbs, Gabriela
    Jalbut, Marla M.
    Neuberg, Donna S.
    Fathi, Amir T.
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1197 - 1200
  • [5] RISK FACTORS FOR INCIDENCE OF HEMORRHAGIC COMPLICATIONS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
    Simonovic, E.
    Macukanovic-Golubovic, L.
    HAEMATOLOGICA, 2017, 102 : 819 - 820
  • [6] Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea
    Wang, Rong
    Shallis, Rory M.
    Huntington, Scott F.
    Zeidan, Amer M.
    Gore, Steven D.
    Davidoff, Amy J.
    Ma, Xiaomei
    Podoltsev, Nikolai A.
    BLOOD, 2019, 134
  • [7] Second primary malignancies in myeloproliferative neoplasms and the role of aspirin
    Marko Lucijanic
    Marko Skelin
    Rajko Kusec
    Leukemia, 2019, 33 : 2554 - 2554
  • [8] Second primary malignancies in myeloproliferative neoplasms and the role of aspirin
    Lucijanic, Marko
    Skelin, Marko
    Kusec, Rajko
    LEUKEMIA, 2019, 33 (10) : 2554 - 2554
  • [9] Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms
    Seguro, Fernanda Salles
    Cardoso Teixeira, Larissa Lane
    da Rosa, Lidiane Ines
    da Silva, Wellington Fernandes
    Nardinelli, Luciana
    Bendit, Israel
    Rocha, Vanderson
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 49 (04) : 667 - 672
  • [10] Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms
    Fernanda Salles Seguro
    Larissa Lane Cardoso Teixeira
    Lidiane Inês da Rosa
    Wellington Fernandes da Silva
    Luciana Nardinelli
    Israel Bendit
    Vanderson Rocha
    Journal of Thrombosis and Thrombolysis, 2020, 49 : 667 - 672